KI-Beratung Beta

Produktbild: Drug-induced Neurological Disorders

Drug-induced Neurological Disorders

Fr. 264.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

This book is a first-of-its kind reference that systematically organizes and describes the adverse effects of drugs on the nervous system. Drug safety is recognized as an important aspect of pharmaceutical companies as well as practice of medicine.  Chapters include case reports of adverse effects of...

Beschreibung

This book is a first-of-its kind reference that systematically organizes and describes the adverse effects of drugs on the nervous system. Drug safety is recognized as an important aspect of pharmaceutical companies as well as practice of medicine. 
Chapters include case reports of adverse effects of drugs that are published as well as reported to drug manufacturers. The book scope is broad as it covers lack of efficacy, drug resistance, drug-disease and drug-drug interactions. This information is used to improve the use of drugs as well as to design better and safer drugs for the future, and is relevant to personalized medicine in trying to match the right drugs to the patients.
Drug-induced Neurological Disorders  offers a unique approach to this important topic by integrating clinical neurology with pharmacology with a focus on effects of drugs on the nervous system including those used for the treatment of neurological disorders as well systemic diseases. Many adverse effects involve multiple systems of the body and the syndromes with predominant effect on the nervous system are included in this book.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

14.07.2021

Abbildungen

XXVII, 604 p. 11 illus.

Verlag Springer

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

14.07.2021

Abbildungen

XXVII, 604 p. 11 illus.

Verlag Springer
Seitenzahl

604

Maße (L/B/H)

26/18.3/3.7 cm

Gewicht

1447 g

Auflage

Fourth Edition 2021

Sprache

Englisch

ISBN

978-3-030-73502-9

Herstelleradresse

Springer-Verlag GmbH
Europaplatz 3
69115 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Drug-induced Neurological Disorders
  • 1. Introduction, history and epidemiology of drug-induced neurological disorders.- 2. Neurologic symptoms as adverse drug reactions.- 3. Role of the blood-brain barrier in effects of drugs on the brain.- 4. Pathomechanisms of drug-induced neurological disorders.- 5. Adverse effects of drugs on the fetal nervous system.- 6. Principles of management of drug-induced neurological disorders.- 7. Methods of drug delivery to the nervous system and DIND.- 8. Neurological complications of anesthesia.- 9. Neurological complications of cancer therapies.- 10. Adverse effects of biological therapies on the nervous system.- 11.Drug-induced aseptic meningitis.- 12. Drug-induced intracranial hypertension.- 13. Drug-induced encephalopathies.- 14. Drug-induced disorders of memory and dementia.- 15. Drug-induced disturbances of consciousness.- 16. Drug-induced neuro-psychiatric disorders.- 17. Neurological effects of drug abuse.- 18. Drug-induced sleep disorders.- 19. Drug-induced seizures.- 20. Drug-induced movement disorders.- 21. Tardive dyskinesia.- 22. Drug-induced headaches.- 23. Drug-induced cerebrovascular disorders.- 24. Drug-induced disorders of cranial nerves.- 25. Drug-induced neurootological disorders.- 26. Drug-induced neuro-ophthalmological disorders.- 27. Drug-induced disorders of smell and taste.- 28. Drug-induced peripheral neuropathies.- 29. Drug-induced disorders of the autonomic nervous system.- 30. Drug-induced neuromuscular disorders.- 31. Drug-induced myopathies.- 32. Drug-induced spinal disorders.- 33. Drug-induced cerebellar disorders.- 34. Eosinophilia-myalgia syndrome.- 35. Drug-induced pituitary disorders.- 36. Serotonin syndrome.- 37. Drug-induced Guillain-Barré syndrome.- 38. Neuroleptic malignant syndrome.